ALX ONCOLOGY HOLDINGS INC
Close on Oct 19, 2026
- Market cap
- $154.63M
- P/E (TTM)
- –
- Dividend yield
- –
About Alx Oncology
Pharmaceutical Preparations, SIC 2834
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on advancing novel cancer therapies to prolong patient survival. Its clinical pipeline centers on two investigational candidates: evorpacept and ALX2004. Evorpacept is an engineered CD47-blocking fusion protein that pairs an affinity-enhanced extracellular domain of SIRPα with an inactivated Fc domain, designed to prevent hematologic toxicities while enabling the immune system to engulf cancer cells in combination with other anti-cancer treatments. The company evaluates evorpacept in clinical studies alongside targeted anti-cancer antibodies, small molecules, and checkpoint inhibitors, notably in combination with trastuzumab and chemotherapy for patients with metastatic HER2-positive breast cancer. ALX2004 is an antibody-drug conjugate targeting epidermal growth factor receptor (EGFR).
The company maintains its principal executive offices in South San Francisco, California. Its clinical research activities involve evaluating investigational therapies across patient populations, with evorpacept having been administered to approximately 800 subjects in clinical trials.
Summary of the business section of Alx Oncology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ALX ONCOLOGY HOLDINGS INC
- Headquarters
- South San Francisco, CA
- Address
- 323 Allerton Avenue 94080
- Phone
- (650) 466-7125
- Website
- alxoncology.com
- Employees
- 43, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Francisco, California
Stock & identifiers
- Ticker
- ALXO
- Exchange
- Nasdaq
- IPO date
- Jul 17, 2020
- Shares outstanding
- 138M, Jul 30, 2026
- Public float
- $18.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1810182
- CUSIP
- 00166B105
- ISIN
- US00166B1052
- EIN
- 85-0642577
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jason Lettmann | CHIEF EXECUTIVE OFFICER, Director | 2,393,474 |
| Shelly Pinto | SVP, FINANCE AND CAO | 87,828 |
| Barbara Klencke | Chief Medical Officer | 120,000 |
| Jeff E. Knight | Chief Dev & Operating Officer | – |
| Harish Shantharam | Chief Financial Officer | 75,000 |
| Jaume Pons | PRESIDENT & CSO | 579,388 |
| Corey S. Goodman | Director | 8,453,038 |
| Rekha Hemrajani | Director | 33,000 |
| J. Scott Garland | Director | – |
| Alan B. Sandler | Director | – |
| Daniel J. Curran | Director | – |
| Chris H. Takimoto | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Jason Lettmann | $2.47M | $1.32M | $1.20M | $10 | – |
| FY2025 Jaume Pons | $0 | $0 | $1.20M | $10 | – |
| FY2024 Jason Lettmann | $6.64M | -$11.21M | $2.69M | $15 | – |
| FY2024 Jaume Pons | $0 | $0 | $2.69M | $15 | – |
| FY2023 Jason Lettmann | $4.86M | $15.23M | $1.34M | $132 | – |
| FY2023 Jaume Pons | $2.75M | $5.62M | $1.34M | $132 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 43 employees, 11 of whom hold Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 25, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 17, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 13, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |